Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Prolonged Use of Bivalirudin 4 Hours After ePCI (COBER Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* De novo lesions~* elective PCI~* Only single coronary artery treated at this time~Exclusion Criteria:~* Those who meet the diagnostic criteria of acute myocardial infarction~* Patients with cardio-genic shock~* Patients with multiple organ failure~* Patients allergic to contrast~* Patients who can not tolerate dual antiplatelet therapy~* Patients who can't tolerate anticoagulation~* Recently infected patients~* Patients with hepatorenal dysfunction~* Thrombotic lesion of coronary artery~* Chronic total coronary occlusion lesion~* Patients with complex coronary bifurcation requiring two stent strategy~* Severe coronary calcified lesion~* Patients with percutaneous coronary angioplasty~* Patients with directional coronary atherectomy or rotational atherectomy~* Patients with drug coated balloon treatment~* Patients with bioabsorbable vascular scaffold implantation~* Previous percutaneous coronary intervention~* Previous coronary artery bypass graft~* Patients with active stage of autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- prolonged continuous use of bivalirudine (Type: EXPERIMENTAL): A total of 165 patients are assigned to group with prolonged continuous use of bivalirudin after randomization schedule.
- bivalirudin use during ePCI (Type: OTHER): A total of 165 patients are assigned to group with bivalirudin use during ePCI after randomization schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).